BioCentury
ARTICLE | Company News

HBMK Pharmaceutical, Hubei Minkang Pharmaceutical Ltd. deal

October 3, 2011 7:00 AM UTC

Hubei Minkang completed its acquisition of HBMK in a stock deal. HBMK shareholders received 33.5 million Hubei Minkang shares valued at $13.4 million based on Hubei's close of $0.40 on Sept. 21, the day before the company announced that the deal closed. The traditional Chinese medicines company became a wholly-owned subsidiary of Hubei (see BioCentury, July 18). ...